A Phase 2 interventional study of Evolocumab and Placebo to Evolocumab in Hyperlipidemia, sponsored by Amgen. Completed at 100 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-15.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.
Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 4th largest by enrollment, is one of 3 that started in 2011, is one of 3 in phase 2, and was the 4th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 631 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 307 across the 21 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
17 studies in Hyperlipidemias by Amgen: none open now, none under way, none of them phase 3. Of 17 finished, 17 (100%) have results posted.
Among the 17 studies in Hyperlipidemias by Amgen, this one is the 4th largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 2, and was the 4th registered.
Amgen’s Hyperlipidemias studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing evolocumab in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 17 in Hyperlipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab (AMG 145) administered every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on percent change from baseline in LDL-C when used in addition to a statin in adults with hypercholesterolemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
Other: Placebo to Evolocumab
Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
Other: Placebo to Evolocumab
Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Biological: Evolocumab
Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Biological: Evolocumab
Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Biological: Evolocumab
Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Administered by subcutaneous injection
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
LDL-C was measured using ultracentrifugation.
Time frame: Baseline and Week 12
Change From Baseline in LDL-C at Week 12
LDL-C was measured using ultracentrifugation.
Time frame: Baseline and Week 12
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12
Time frame: Baseline and Week 12
This study enrolled adults aged 18 - 80 years who were on a statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks, and fasting low-density lipoprotein cholesterol (LDL-C) ≥ 85 mg/dL. The first patient enrolled on 18 July 2011 and the last patient enrolled on 22 December 2011.
| Milestone | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|
| Started | 78 | 79 | 79 | 79 | 78 | 79 | 79 | 80 |
| Received treatment | 78 | 77 | 79 | 79 | 78 | 79 | 79 | 80 |
| Completed | 78 | 79 | 79 | 79 | 77 | 79 | 79 | 80 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
LDL-C was measured using ultracentrifugation.
| percent change | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 | 2.76 ± 2.39 | -0.98 ± 2.51 | -39.06 ± 2.39 | -57.48 ± 2.39 | -63.34 ± 2.40 | -42.82 ± 2.52 | -50.98 ± 2.51 | -51.31 ± 2.53 |
LDL-C was measured using ultracentrifugation.
| mg/dL | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in LDL-C at Week 12 | -0.2 ± 3.4 | -3.2 ± 3.3 | -50.9 ± 3.4 | -77.6 ± 3.5 | -79.5 ± 3.4 | -53.7 ± 3.3 | -64.3 ± 3.3 | -64.3 ± 3.3 |
| percent change | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12 | 2.21 ± 2.20 | -1.26 ± 2.26 | -36.23 ± 2.20 | -53.21 ± 2.20 | -59.19 ± 2.21 | -39.05 ± 2.27 | -47.05 ± 2.26 | -48.83 ± 2.27 |
| percent change | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 12 | 5.86 ± 2.15 | 3.22 ± 2.25 | -28.88 ± 2.15 | -44.29 ± 2.14 | -50.59 ± 2.15 | -31.16 ± 2.26 | -37.55 ± 2.26 | -38.81 ± 2.27 |
| percent change | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12 | 2.64 ± 1.97 | -2.00 ± 1.90 | -28.76 ± 1.97 | -40.73 ± 1.97 | -45.09 ± 1.98 | -29.73 ± 1.91 | -37.97 ± 1.91 | -37.66 ± 1.92 |
| percent change | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12 | -0.30 ± 2.13 | -0.35 ± 2.38 | -35.04 ± 2.13 | -47.60 ± 2.12 | -53.73 ± 2.14 | -34.11 ± 2.40 | -42.74 ± 2.39 | -43.28 ± 2.40 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | — | 4/78 (5.1%) | 15/78 (19.2%) |
| Placebo Q4W | — | 0/77 (0%) | 17/77 (22.1%) |
| Evolocumab 70 mg Q2W | — | 0/79 (0%) | 20/79 (25.3%) |
| Evolocumab 105 mg Q2W | — | 1/79 (1.3%) | 28/79 (35.4%) |
| Evolocumab 140 mg Q2W | — | 4/78 (5.1%) | 27/78 (34.6%) |
| Evolocumab 280 mg Q4W | — | 2/79 (2.5%) | 21/79 (26.6%) |
| Evolocumab 350 mg Q4W | — | 2/79 (2.5%) | 23/79 (29.1%) |
| Evolocumab 420 mg Q4W | — | 2/80 (2.5%) | 30/80 (37.5%) |
| Event | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/78 | 0/77 | 0/79 | 0/79 | 1/78 | 0/79 | 0/79 | 0/80 |
| Cardiac failure congestiveCardiac disorders | 0/78 | 0/77 | 0/79 | 0/79 | 1/78 | 0/79 | 0/79 | 0/80 |
| Coronary artery diseaseCardiac disorders | 0/78 | 0/77 | 0/79 | 0/79 | 1/78 | 0/79 | 0/79 | 0/80 |
| TachycardiaCardiac disorders | 0/78 | 0/77 | 0/79 | 0/79 | 1/78 | 0/79 | 0/79 | 0/80 |
| PainGeneral disorders | 0/78 | 0/77 | 0/79 | 0/79 | 1/78 | 0/79 | 0/79 | 0/80 |
| Cholecystitis acuteHepatobiliary disorders | 1/78 | 0/77 | 0/79 | 0/79 | 0/78 | 0/79 | 0/79 | 0/80 |
| CellulitisInfections and infestations | 0/78 | 0/77 | 0/79 | 0/79 | 1/78 | 0/79 | 1/79 | 0/80 |
| PneumoniaInfections and infestations | 0/78 | 0/77 | 0/79 | 0/79 | 1/78 | 0/79 | 1/79 | 0/80 |
| Urinary tract infectionInfections and infestations | 1/78 | 0/77 | 0/79 | 0/79 | 0/78 | 0/79 | 0/79 | 0/80 |
| Acetabulum fractureInjury, poisoning and procedural complications | 0/78 | 0/77 | 0/79 | 0/79 | 1/78 | 0/79 | 0/79 | 0/80 |
| Event | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/78 | 5/77 | 9/79 | 8/79 | 7/78 | 8/79 | 8/79 | 8/80 |
| InfluenzaInfections and infestations | 2/78 | 1/77 | 3/79 | 3/79 | 6/78 | 0/79 | 1/79 | 0/80 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/78 | 2/77 | 3/79 | 3/79 | 0/78 | 6/79 | 1/79 | 3/80 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/78 | 3/77 | 4/79 | 5/79 | 2/78 | 0/79 | 1/79 | 1/80 |
| FatigueGeneral disorders | 1/78 | 0/77 | 0/79 | 1/79 | 1/78 | 0/79 | 2/79 | 5/80 |
| Upper respiratory tract infectionInfections and infestations | 2/78 | 2/77 | 2/79 | 3/79 | 4/78 | 0/79 | 0/79 | 4/80 |
| HeadacheNervous system disorders | 2/78 | 0/77 | 1/79 | 1/79 | 4/78 | 1/79 | 2/79 | 2/80 |
| DiarrhoeaGastrointestinal disorders | 2/78 | 2/77 | 1/79 | 4/79 | 2/78 | 1/79 | 2/79 | 3/80 |
| NauseaGastrointestinal disorders | 1/78 | 0/77 | 0/79 | 1/79 | 3/78 | 4/79 | 3/79 | 4/80 |
| Back painMusculoskeletal and connective tissue disorders | 1/78 | 1/77 | 0/79 | 2/79 | 2/78 | 4/79 | 3/79 | 3/80 |
Full analysis set (all randomized participants who received at least 1 dose of investigational product).
| Age, Continuous(years) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 60.2 ± 8.8 | 60.1 ± 9.6 | 59.4 ± 9.9 | 58.8 ± 9.7 | 62.4 ± 10.2 | 60.3 ± 8.4 | 61.9 ± 8.8 | 60.9 ± 10.3 | 60.5 ± 9.5 |
| Sex: Female, Male(Participants) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 42 | 41 | 44 | 25 | 45 | 40 | 38 | 44 | 319 |
| Male | 36 | 36 | 35 | 54 | 33 | 39 | 41 | 36 | 310 |
| Race/Ethnicity, Customized(participants) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 3 |
| Asian | 0 | 2 | 1 | 3 | 1 | 2 | 2 | 1 | 12 |
| Black or African American | 6 | 0 | 6 | 8 | 9 | 8 | 4 | 9 | 50 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 3 |
| White | 72 | 74 | 72 | 67 | 67 | 64 | 72 | 70 | 558 |
| Other | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 3 |
| Race/Ethnicity, Customized(participants) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 6 | 5 | 0 | 6 | 1 | 0 | 2 | 21 |
| Not Hispanic or Latino | 77 | 71 | 74 | 79 | 72 | 78 | 79 | 78 | 608 |
| Stratification Factor: LDL-C Level(participants) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| < 130 mg/dL | 51 | 51 | 51 | 51 | 52 | 51 | 52 | 53 | 412 |
| ≥ 130 mg/dL | 27 | 26 | 28 | 28 | 26 | 28 | 27 | 27 | 217 |
| Stratification Factor: Baseline Ezetimibe Use(participants) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| No | 71 | 69 | 72 | 72 | 71 | 72 | 72 | 73 | 572 |
| Yes | 7 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 57 |
| LDL-C Concentration(mg/dL) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 122.2 ± 27.1 | 124.9 ± 30.6 | 121.4 ± 24.4 | 127.4 ± 32.1 | 120.9 ± 25.1 | 122.0 ± 28.8 | 123.2 ± 27.1 | 120.8 ± 26.5 | 122.8 ± 27.7 |
| Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 146.9 ± 29.9 | 150.2 ± 36.5 | 145.3 ± 29.9 | 151.2 ± 37.2 | 145.3 ± 26.2 | 146.3 ± 33.3 | 150.0 ± 29.1 | 144.4 ± 31.2 | 147.4 ± 31.8 |
3 further baseline measures are reported on the registry.
Ran from Jul 2011 to primary completion in Apr 2012, 9 months.
Results were first posted in Oct 2015, 3 years 5 months after primary completion. A results delay was requested in Mar 2013.
Of 30 phase 2 interventional studies under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab